A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-hodgkin lymphoma (NHL)

The University of Virginia Cancer Center seeks participants 18 years old or above to participate in a study that looks at a new treatment for follicular or marginal zone lymphoma that has not responded to or returned after previous treatments. The JCAR-017 treatment works on the T-cells in the body (part of the immune system).

Participation on this study involves up to 26 weeks. Participants are also required to take part in a 15-year long-term follow up study. Study-related tests and procedures and study drug will be covered by the study sponsor.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04245839